MiRus Enhances Cervical Surgery with Groundbreaking Technology
MiRus is proud to announce a significant advancement in cervical and upper thoracic spine surgery with the introduction of the EUROPA® Posterior Cervical Fusion System. This innovative technology has been specifically designed to help patients who qualify for Medicare coverage, providing them with enhanced surgical options that utilize proprietary rhenium alloys.
As healthcare costs continue to rise, hospitals face the challenge of offering effective treatment to those who need it most. Complex posterior cervical procedures often pose significant hurdles, but the EUROPA® PCF system has received the prestigious Breakthrough Device Designation from the FDA. This recognition highlights the uniqueness of the technology and its potential to improve patient care and access.
Dr. Jose A. Canseco, an Assistant Professor of Orthopedic Surgery at Thomas Jefferson University, shared insights into the system's capabilities. "This low-profile system, constructed from next-generation alloys, enables me to tackle surgical tasks at both C6 and C7 levels without the need to skip critical segments in intricate cervico-thoracic reconstructions. Its design alleviates the bulk associated with quad-rod structures and cumbersome connectors, which are often barriers to optimal surgical outcomes. The seamless transition rod design, spanning from 2.9 mm to 4.5 mm, is particularly valuable in complex cases, such as chin-on-chest deformities, where precision is crucial," he remarked.
Dr. Canseco also expressed his enthusiasm about bringing this advanced technology to local institutions like Capital Health, which prioritize innovation to enhance patient outcomes.
Mahesh Krishnan, Chief Commercial Officer at MiRus, comments on the broader implications of the NTAP designation awarded by CMS. "The recognition means that more patients can access this cutting-edge technology, allowing hospitals to treat a larger number of Medicare patients with the added incentive to offset some financial burdens associated with healthcare delivery. CxOs are actively seeking to integrate this state-of-the-art technology into their surgical protocols to serve patients better in today’s complex healthcare environment," he noted.
At MiRus, innovation continues to be a driving force, particularly with the use of the MoRe® Superalloy across multiple applications in Extremities and Structural Heart health. This approach underscores our commitment to delivering clinical advantages and expanding our impact on patient care. The NTAP designation for the EUROPA® PCF system is just a glimpse of what’s to come as we strive to bring more meaningful advancements in the future.
About MiRus, LLC.
MiRus is a forward-thinking life sciences company situated in Marietta, Georgia. The firm has pioneered the development of unique biomaterials, implants, and procedural solutions aimed at addressing complications in spine, orthopedic, and structural heart diseases. Inspired by NASA's groundbreaking materials technology used in rocket engines, MiRus has engineered rhenium-based medical alloys that are reshaping surgical outcomes by making procedures less invasive and implants more durable and reliable.
Frequently Asked Questions
What is the EUROPA® Posterior Cervical Fusion System?
The EUROPA® PCF system is an innovative surgical technology designed to improve outcomes in cervical and upper thoracic spine surgeries. It utilizes proprietary rhenium alloys to enhance the treatment process.
How does the NTAP designation impact hospitals?
The NTAP designation allows hospitals to treat more Medicare patients, providing them with financial incentives to integrate advanced technologies like the EUROPA® PCF system.
Who developed the EUROPA® PCF system?
MiRus, a life sciences company based in Georgia, developed this system aiming to improve patient outcomes through their proprietary technology and materials.
What are the advantages of using the EUROPA® system?
The EUROPA® system offers a low-profile design, minimizes the need for bulky equipment, and enhances precision in surgeries, especially in challenging cases.
What is MiRus's commitment to innovation?
MiRus is dedicated to continuous innovation and improving patient care through advanced materials and solutions in the fields of spine, orthopedic, and structural heart treatments.
